

# Vicore announces the Nomination Committee for the 2025 Annual General Meeting

**Stockholm, November 4, 2024 – Vicore Pharma Holding AB (publ) (STO: VICO) (“Vicore”), a clinical-stage pharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), has appointed the Nomination Committee for the 2025 Annual General Meeting. The three largest shareholders as of August 31, 2024, have each appointed a member to the Nomination Committee.**

The Nomination Committee consists of Staffan Lindstrand, appointed by HealthCap VII L.P., Jan Särilvik, appointed by the Fourth Swedish National Pension Fund, and Ivo Staijen, appointed by HBM Healthcare Investments (Cayman) Ltd. Vicore’s chairman, Hans Schikan, is also a member and acts as the convener of the Committee.

The task of the Nomination Committee is to prepare and present proposals for the number of board members to be elected by the AGM, the election of a chairman and other members of the board, board fees, remuneration for committee work, election of a chairman to the Annual General Meeting, election of auditors, and auditors’ fees, and proposals for rules for the appointment of a nomination committee for the Annual General Meeting 2026.

The Annual General Meeting will take place on May 6, 2025. Shareholders who wish to submit their comments or submit proposals to the Nomination Committee may do so by January 15, 2024, by email to [info@vicorepharma.com](mailto:info@vicorepharma.com) or by letter to Vicore Pharma Holding AB (publ), Kornhamnstorg 53, 111 27 Stockholm. The Nomination Committee's proposal will be presented in the notice convening the AGM and on the company's website.

**For further information, please contact:**

Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, [megan.richards@vicorepharma.com](mailto:megan.richards@vicorepharma.com)

Hans Jeppsson, CFO, tel: +46 70 553 14 65, [hans.jeppsson@vicorepharma.com](mailto:hans.jeppsson@vicorepharma.com)

*This information was submitted for publication on November 4, 2024, at 09:00 CET.*

**About Vicore Pharma Holding AB**

*Vicore is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is advancing a portfolio of therapies in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) being investigated in a global Phase 2b trial in IPF. Almee™ is an investigational digital therapeutic in clinical development that is based on cognitive behavioral therapy and created to address the psychological impact of living with pulmonary fibrosis. Almee has received Breakthrough Device Designation from the FDA, which the company believes reflects its potential to have transformative impact. Using its expertise in ATRAG chemistry and biology, Vicore is further developing its pipeline with several new therapies across additional indications. The company’s shares are listed on Nasdaq Stockholm’s main market (VICO).*

[www.vicorepharma.com](http://www.vicorepharma.com)

**Attachments**

[Vicore announces the Nomination Committee for the 2025 Annual General Meeting](#)